177lu-ctr-fapi

Neuroendocrine Tumor (NET)

Xijing HospitalN/AActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

61 Active assets in the Neuroendocrine Tumor (NET) cohort.

Asset / Sponsor	Phase	Rating
Irinotecan First Affiliated Hospital Xi'an Jiaotong University	Phase 4	BB
Bms-907351 Fox Chase Cancer Center	Phase 3	BB
Eloxatin ITM Solucin GmbH	Phase 3	BB
FLUOROURACILUM ITM Solucin GmbH	Phase 3	BB
Pasireotide RECORDATI GROUP	Phase 4	BB

View all 50 →

Same molecule, other indications

177lu-ctr-fapi is also rated in:

metastatic neoplasmDormant

CC

Indicative ·

43 / 100

pancreatic neoplasmDormant

C

Indicative ·

33 / 100

pancreatic ductal adenocarcinomaDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.